title: Fine specificity of the antibody response to Epstein-Barr nuclear antigen-2 and other Epstein-Barr virus proteins in patients with clinically isolated syndrome: A peptide microarray-based case-control study.
abstract: We analyzed the fine specificity of antibodies to Epstein-Barr nuclear antigen-2 (EBNA-2) and other Epstein-Barr virus (EBV) proteins in 29 patients with clinically isolated syndrome (CIS, the first clinical manifestation of multiple sclerosis [MS]) and 29 controls with a peptide microarray containing 117 overlapping peptides representing the full-length EBNA-2 protein and 71 peptides from 8 further EBV proteins. While EBV peptide antibodies were elevated in CIS, suggesting that EBV contributes to MS early during disease development, they discriminated groups only slightly better than EBNA-1 antibodies. Thus, the additional value of EBV peptide antibodies as diagnostic biomarkers for CIS appears moderate.
authors.affiliation: Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Ludwig
authors.initials: L
authors.lastname: Schlemm
authors.affiliation: Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Clinical and Experimental Multiple Sclerosis Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany; NeuroCure Clinical Research Center, NeuroCure Cluster of Excellence, Charité - Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: René Markus
authors.initials: RM
authors.lastname: Giess
authors.affiliation: Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Clinical and Experimental Multiple Sclerosis Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany; NeuroCure Clinical Research Center, NeuroCure Cluster of Excellence, Charité - Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Ludwig
authors.initials: L
authors.lastname: Rasche
authors.affiliation: Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Clinical and Experimental Multiple Sclerosis Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany; NeuroCure Clinical Research Center, NeuroCure Cluster of Excellence, Charité - Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Catherina
authors.initials: C
authors.lastname: Pfuhl
authors.affiliation: Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Clinical and Experimental Multiple Sclerosis Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany; NeuroCure Clinical Research Center, NeuroCure Cluster of Excellence, Charité - Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Katharina
authors.initials: K
authors.lastname: Wakonig
authors.affiliation: Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Clinical and Experimental Multiple Sclerosis Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany; NeuroCure Clinical Research Center, NeuroCure Cluster of Excellence, Charité - Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Janina Ruth
authors.initials: JR
authors.lastname: Behrens
authors.affiliation: Institute for Medical Immunology, Charité - Universitätsmedizin Berlin, Germany.
authors.forename: Carmen
authors.initials: C
authors.lastname: Scheibenbogen
authors.affiliation: NeuroCure Clinical Research Center, NeuroCure Cluster of Excellence, Charité - Universitätsmedizin Berlin, Berlin, Germany; Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany.
authors.forename: Judith
authors.initials: J
authors.lastname: Bellmann-Strobl
authors.affiliation: Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Clinical and Experimental Multiple Sclerosis Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany; NeuroCure Clinical Research Center, NeuroCure Cluster of Excellence, Charité - Universitätsmedizin Berlin, Berlin, Germany; Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany.
authors.forename: Friedemann
authors.initials: F
authors.lastname: Paul
authors.affiliation: JPT Peptide Technologies GmbH, Berlin, Germany.
authors.forename: Ulf
authors.initials: U
authors.lastname: Reimer
authors.affiliation: Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Clinical and Experimental Multiple Sclerosis Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany. Electronic address: klemens.ruprecht@charite.de.
authors.forename: Klemens
authors.initials: K
authors.lastname: Ruprecht
mesh_terms: D000328:Adult; D000818:Animals; D000914:Antibodies, Viral / Q000378:metabolism*; D000917:Antibody Formation / Q000502:physiology*; D004185:Disability Evaluation; D004797:Enzyme-Linked Immunosorbent Assay; D020031:Epstein-Barr Virus Infections / Q000150:complications* / Q000276:immunology; D019309:Epstein-Barr Virus Nuclear Antigens / Q000276:immunology*; D005260:Female; D004854:Herpesvirus 4, Human / Q000276:immunology / Q000472:pathogenicity; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008279:Magnetic Resonance Imaging; D008297:Male; D008807:Mice, Inbred BALB C; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000097:blood / Q000000981:diagnostic imaging / Q000209:etiology* / Q000276:immunology; D040081:Protein Array Analysis; D018709:Statistics, Nonparametric; D014764:Viral Proteins / Q000276:immunology*; D055815:Young Adult
chemical_list: D000914:Antibodies, Viral; C402641:EBNA-2 protein, Human herpesvirus 4; D019309:Epstein-Barr Virus Nuclear Antigens; D007074:Immunoglobulin G; D014764:Viral Proteins; C417029:EBV-encoded nuclear antigen 1
keywords: Antibodies; Clinically isolated syndrome; Epstein-Barr nuclear antigen; Epstein-Barr virus; Multiple sclerosis; Peptide microarray